Advanced search    

Search: authors:"Christopher H Crane"

12 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer

The role of radiation in locally advanced unresectable pancreatic cancer (LAPC) is controversial. Randomized trials evaluating standard doses of chemoradiation have not shown a significant benefit from the use of consolidative radiation. Results from non-randomized studies of 3–5-fraction stereotactic body radiotherapy (SBRT) have been similar to standard chemoradiation, but with...

Is Personalization of Care Coming to Pancreatic Oncology?

Christopher H. Crane 0 0 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX - The results of a phase II trial evaluating adjuvant treatment using a

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

Purpose To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation (CRT) in unresectable pancreatic cancer. Methods Seventeen patients with CT-staged, biopsy-proven unresectable pancreatic cancer were enrolled between 3/2008 and 10/2010. Prior chemotherapy was permitted. Two...

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

Background Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic CCA have diverse clinical presentations. Next generation sequencing (NGS) technology may identify the genetic differences between these entities and identify molecular subgroups for targeted therapeutics. Methods We describe successful NGS-based testing of 75 CCA patients along with the...

Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma

Background A strong dose-volume relationship exists between the amount of small bowel receiving low- to intermediate-doses of radiation and the rates of acute, severe gastrointestinal toxicity, principally diarrhea. There is considerable interest in the application of highly conformal treatment approaches, such as intensity-modulated radiation therapy (IMRT), to reduce dose to...

Reirradiation to the abdomen for gastrointestinal malignancies

Background Reirradiation to the abdomen could potentially play a role in palliation of symptoms or local control in patients with gastrointestinal malignancies. Our goal was to retrospectively determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal cancer patients treated with reirradiation to the abdomen. Methods Between November 2002...

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

Christopher H. Crane 4 Jeffrey H. Lee 3 Eric P. Tamm 8 James L. Abbruzzese 1 Douglas B. Evans 7 M. H. G. Katz e-mail: 0 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated

Christopher H Crane 2 0 Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center , Houston , USA 1 Department of Gastrointestinal Medical Oncology, The University of Texas M. D

Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma

Introduction Actual 5-year survival rates of 10–18% have been reported for patients with resected pancreatic adenocarcinoma (PC), but the use of multimodality therapy was uncommon in these series. We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy. Methods We analyzed 329 consecutive patients...